{
    "paper_id": "PMC7138375",
    "metadata": {
        "title": "Pand\u00e9mie COVID-19\u00a0: impact sur le systeme cardiovasculaire. Donn\u00e9es disponibles au 1er avril 2020",
        "authors": [
            {
                "first": "B.",
                "middle": [],
                "last": "El\u00a0Boussadani",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "C.",
                "middle": [],
                "last": "Benajiba",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "A.",
                "middle": [],
                "last": "Aajal",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "A.",
                "middle": [],
                "last": "Ait\u00a0Brik",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "O.",
                "middle": [],
                "last": "Ammour",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "J.",
                "middle": [],
                "last": "El\u00a0Hangouch",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "O.",
                "middle": [],
                "last": "Oussama",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "B.",
                "middle": [],
                "last": "Oussama",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "N.",
                "middle": [],
                "last": "Tahiri",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Z.",
                "middle": [],
                "last": "Raissuni",
                "suffix": "",
                "email": "zainab.raissouni@hotmail.com",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "L\u2019infection \u00e0 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appel\u00e9e Coronavirus Disease 2019 (COVID-19) a pris naissance en Chine en d\u00e9cembre 2019. Elle est \u00e0 l\u2019origine de pneumonies potentiellement mortelles. L\u2019infection est d\u00e9clar\u00e9e pand\u00e9mie par l\u2019OMS le 11 mars 2020. Le 01 avril 2020 l\u2019OMS d\u00e9nombre 911 541 cas confirm\u00e9s de COVID-19, et 45 532 d\u00e9c\u00e8s.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Le COVID-19 peut avoir un impact direct sur le syst\u00e8me cardiovasculaire. Les maladies cardiovasculaires pr\u00e9existantes peuvent pr\u00e9disposer \u00e0 une infection par COVID-19 ou l\u2019aggraver. Ainsi l\u2019impact de l\u2019infection semble \u00eatre plus intense si l\u2019h\u00f4te pr\u00e9sente des comorbidit\u00e9s cardiovasculaires, d\u2019autant plus qu\u2019il s\u2019agit le plus souvent de sujets \u00e2g\u00e9s fragiles et \u00e0 immunit\u00e9 r\u00e9duite. Les th\u00e9rapies pour COVID-19 peuvent entra\u00eener des effets ind\u00e9sirables cardiovasculaires \u00e0 la phase aigu\u00eb potentiellement graves et n\u00e9cessitant une surveillance rapproch\u00e9e. Les personnes atteintes de maladies cardiovasculaires infect\u00e9es par le virus ont un risque plus \u00e9lev\u00e9 d\u2019effets ind\u00e9sirables, et sont consid\u00e9r\u00e9es de mauvais pronostic. Des effets cardiovasculaires chroniques passant par une perturbation du m\u00e9tabolisme lipidique sont \u00e9galement des cons\u00e9quences connues des coronavirus.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "L\u2019objectif de cette revue est de caract\u00e9riser l\u2019impact cardiovasculaire du COVID-19 et ses cons\u00e9quences potentielles chez les patients atteints de maladie cardiovasculaire \u00e9tablie. Nous allons \u00e9galement aborder les modalit\u00e9s de surveillance des traitements propos\u00e9s dans le COVID-19.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Les infections virales respiratoires repr\u00e9sentent une part tr\u00e8s importante de la morbidit\u00e9 observ\u00e9e en pratique communautaire et hospitali\u00e8re et demeurent la principale cause de mortalit\u00e9 d\u2019origine infectieuse. Elle reste une source majeure de pand\u00e9mies mondiales en raison de la transmission interhumaine rapide par voie respiratoire [1].",
            "cite_spans": [
                {
                    "start": 335,
                    "end": 338,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Depuis 1510, 14 pand\u00e9mies se sont succ\u00e9d\u00e9es, dont la grippe espagnole en 1918 consid\u00e9r\u00e9e comme la plus grave [2]. L\u2019\u00e9pid\u00e9mie de SRAS (syndrome respiratoire aigu s\u00e9v\u00e8re li\u00e9 au coronavirus) en 2002 a \u00e9t\u00e9 responsable de 916 d\u00e9c\u00e8s parmi plus de 8000 patients dans 29 pays, suivis par l\u2019\u00e9mergence du MERS-COV (Coronavirus du syndrome respiratoire du Moyen-Orient) en 2012, avec 800 d\u00e9c\u00e8s parmi 2254 patients dans 27 pays [3].",
            "cite_spans": [
                {
                    "start": 109,
                    "end": 112,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 416,
                    "end": 419,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19",
            "ref_spans": []
        },
        {
            "text": "La grippe aviaire et porcine demeure une pr\u00e9occupation pour l\u2019OMS, m\u00eame si la mortalit\u00e9 reste similaire aux virus saisonniers pendant pand\u00e9mie de H1N1 en 2009 [1].",
            "cite_spans": [
                {
                    "start": 159,
                    "end": 162,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Fin 2019, une cohorte de patients pr\u00e9sentant une pneumopathie d\u2019\u00e9tiologie inconnue d\u00e9clar\u00e9e \u00e0 Wuhan en Chine, annonce le d\u00e9but de la pand\u00e9mie COVID-19. Le 01 avril 2020, un total de 911 541 confirm\u00e9s cas (dont 45 532 d\u00e9c\u00e8s dans 152 pays) ont \u00e9t\u00e9 r\u00e9pertori\u00e9s par l\u2019Organisation mondiale de la sant\u00e9. Bien que COVID-19 semble avoir une plus grande contagiosit\u00e9, sa mortalit\u00e9 est plus faible que le SRAS et MERS-COV. Cette infection COVID-19 est secondaire \u00e0 un virus d\u2019origine zoonotique appel\u00e9 par l\u2019OMS coronavirus 2 du syndrome respiratoire aigu (SARS-CoV-2).",
            "cite_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Les manifestations cliniques sont domin\u00e9es par des sympt\u00f4mes respiratoires pouvant aller de la simple toux ou g\u00e8ne laryng\u00e9e jusqu\u2019au SDRA (syndrome de d\u00e9tresse respiratoire aigu).",
            "cite_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19",
            "ref_spans": []
        },
        {
            "text": "L\u2019atteinte cardiaque dans le COVID est pr\u00e9sente et grave, en effet le virus a un double effet au niveau cardiovasculaire : l\u2019infection sera plus intense si l\u2019h\u00f4te poss\u00e8de des comorbidit\u00e9s cardiovasculaires et, le virus peut lui-m\u00eame causer des l\u00e9sions cardiovasculaires potentiellement mortelles.",
            "cite_spans": [],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19",
            "ref_spans": []
        },
        {
            "text": "En Italie on compte (52 %) de patient avec des ant\u00e9c\u00e9dents de maladie cardiovasculaire, 30 % souffrant de coronaropathie et 22 % avec un trouble du rythme de type fibrillation atriale [4]. Le Tableau 1\nr\u00e9sume les principaux facteurs de risque et situations cardiaques associ\u00e9es au COVID-19.",
            "cite_spans": [
                {
                    "start": 184,
                    "end": 187,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19",
            "ref_spans": [
                {
                    "start": 192,
                    "end": 201,
                    "mention": "Tableau 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "L\u2019atteinte cardiaque directe rapport\u00e9e chez les patients hospitalis\u00e9s est estim\u00e9e entre 7 et 17 % en fonction des s\u00e9ries, et constitue 59 % des d\u00e9c\u00e8s relatifs au SARS-COV 2 [5]. N\u00e9anmoins il s\u2019agit des complications observ\u00e9es uniquement chez les patients hospitalis\u00e9s et non pas sur l\u2019ensemble des sujets infect\u00e9s (Tableau 2\n).",
            "cite_spans": [
                {
                    "start": 173,
                    "end": 176,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "section": "\u00c9pid\u00e9miologie, caract\u00e9ristiques cliniques du COVID-19",
            "ref_spans": [
                {
                    "start": 315,
                    "end": 324,
                    "mention": "Tableau 2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Atteinte myocardique directe via le r\u00e9cepteur de l\u2019enzyme de conversion de l\u2019angiotensine 2 (ACE2), que les cardiomyocytes expriment de mani\u00e8re importante. Cela pourrait \u00eatre \u00e0 l\u2019origine de v\u00e9ritables myocardites ; Selon l\u2019\u00e9tude d\u2019Oudit, l\u2019ARN viral du SRAS-CoV a \u00e9t\u00e9 d\u00e9tect\u00e9 dans 35 % des c\u0153urs humains autopsi\u00e9s pendant l\u2019\u00e9pid\u00e9mie de SRAS \u00e0 Toronto [10]. Les m\u00eames auteurs ont confirm\u00e9 que le SARS-CoV peut causer une l\u00e9sion myocardique d\u00e9pendante de l\u2019ACE2 (ACE2-dependent myocardial infection) [12], identifi\u00e9 comme un r\u00e9cepteur fonctionnel pour les coronavirus (la mod\u00e9lisation mol\u00e9culaire une grande similitude structurelle entre les domaines r\u00e9cepteurs du SRAS-CoV et SARS-COV 2) [13].",
            "cite_spans": [
                {
                    "start": 351,
                    "end": 355,
                    "mention": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 498,
                    "end": 502,
                    "mention": "[12]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 687,
                    "end": 691,
                    "mention": "[13]",
                    "ref_id": "BIBREF12"
                }
            ],
            "section": "Atteinte myocardique directe ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Atteinte myocardique indirecte par infarctus de type 1 (rupture de plaque favoris\u00e9e par l\u2019infection comme avec la grippe) ou de type 2 (secondaire \u00e0 une inad\u00e9quation de la demande et des apports myocardiques en oxyg\u00e8ne secondaire \u00e0 l\u2019insuffisance respiratoire, orage cytokinique).",
            "cite_spans": [],
            "section": "Atteinte myocardique indirecte par infarctus ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "L\u00e9sion myocardique aigu\u00eb (myocardial injury) : un certain nombre de malades admis pour une pneumopathie hypox\u00e9miante et/ou un syndrome de d\u00e9tresse respiratoire aigu\u00eb dans le cadre du COVID-19 d\u00e9velopperont des l\u00e9sions myocardiques aigu\u00ebs d\u00e9finies par une augmentation et ou baisse de la troponine associ\u00e9e \u00e0 une atteinte myocardique [14], [15]. Des diff\u00e9rences significatives en ce qui concerne les taux de la troponine ont \u00e9t\u00e9 not\u00e9es entre les patients gu\u00e9ris et ceux d\u00e9c\u00e9d\u00e9s [16]. Dans une m\u00e9ta-analyse ayant regroup\u00e9 341 patients, l\u2019\u00e9l\u00e9vation de la troponine \u00e9tait plus importante dans les formes graves du COVID-19 et s\u2019associe \u00e0 un pronostic p\u00e9joratif [17], [18]. Cependant, la troponine peut \u00eatre \u00e9lev\u00e9e chez les patients avec insuffisance r\u00e9nale chronique ou ceux qui d\u00e9veloppent une insuffisance r\u00e9nale aigu\u00eb dans le cadre du sepsis.",
            "cite_spans": [
                {
                    "start": 333,
                    "end": 337,
                    "mention": "[14]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 339,
                    "end": 343,
                    "mention": "[15]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 477,
                    "end": 481,
                    "mention": "[16]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 657,
                    "end": 661,
                    "mention": "[17]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 663,
                    "end": 667,
                    "mention": "[18]",
                    "ref_id": "BIBREF17"
                }
            ],
            "section": "L\u00e9sion myocardique aigu\u00eb ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Compte tenu de la fr\u00e9quence et de la nature non sp\u00e9cifique de l\u2019\u00e9l\u00e9vation de la troponine chez les patients infect\u00e9s par COVID-19, il est conseill\u00e9 aux cliniciens de mesurer la troponine uniquement si le diagnostic d\u2019infarctus aigu ou de myocardite est suspect\u00e9. L\u2019\u00e9l\u00e9vation de la troponine et du BNP doit \u00eatre interpr\u00e9t\u00e9e dans le contexte global de l\u2019infection (en confrontation avec les donn\u00e9es cliniques et d\u2019autres techniques d\u2019imagerie).",
            "cite_spans": [],
            "section": "L\u00e9sion myocardique aigu\u00eb ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Sur une s\u00e9rie de 150 cas de COVID-19, 68 d\u00e9c\u00e8s ont \u00e9t\u00e9 r\u00e9pertori\u00e9s avec 27 cas de myocardite dont 5 dites fulminantes [10]. D\u2019autres auteurs ont d\u00e9crit des d\u00e9c\u00e8s sur des formes fulminantes avec des r\u00e9sultats d\u2019autopsie montrant un infiltrat mononucl\u00e9aire dans le tissu myocardique [19], [20]. Une observation publi\u00e9e dans l\u2019EHJ a montr\u00e9 l\u2019efficacit\u00e9 de l\u2019association cortico\u00efdes immunoglobulines dans le traitement d\u2019un cas de myocardite fulminante \u00e0 coronavirus [21].",
            "cite_spans": [
                {
                    "start": 118,
                    "end": 122,
                    "mention": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 281,
                    "end": 285,
                    "mention": "[19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 287,
                    "end": 291,
                    "mention": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 463,
                    "end": 467,
                    "mention": "[21]",
                    "ref_id": "BIBREF20"
                }
            ],
            "section": "Myocardite ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Dans une cohorte de 137 patients admis pour COVID-19, 7,3 % ont pr\u00e9sent\u00e9 des palpitations [22]. La moiti\u00e9 des patients hospitalis\u00e9s en USI ont pr\u00e9sent\u00e9 une arythmie cardiaque, sans pr\u00e9ciser le type de ces troubles [8]. Cette pr\u00e9valence \u00e9lev\u00e9e peut \u00eatre expliqu\u00e9e par les troubles m\u00e9taboliques, hypoxie, stress neurohormonal et inflammatoire dans le contexte du SDRA. Cependant, il faut toujours penser \u00e0 une myocardite devant une arythmie maligne avec l\u00e9sion myocardique aigu\u00eb [16], [23]. Les extrasystoles ventriculaires (ESV) et l\u2019amplitude des QRS sont \u00e0 surveiller. Ces myocardites fulminantes entra\u00eenent une diminution tr\u00e8s rapide de l\u2019amplitude du QRS.",
            "cite_spans": [
                {
                    "start": 90,
                    "end": 94,
                    "mention": "[22]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 214,
                    "end": 217,
                    "mention": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 477,
                    "end": 481,
                    "mention": "[16]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 483,
                    "end": 487,
                    "mention": "[23]",
                    "ref_id": "BIBREF22"
                }
            ],
            "section": "Arythmie cardiaque ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Dans la s\u00e9rie de Zhou et al. [7], une insuffisance cardiaque a \u00e9t\u00e9 observ\u00e9e chez 23 % des patients pr\u00e9sentant une COVID-19 en rapport surtout avec une d\u00e9compensation d\u2019une dysfonction ventriculaire gauche pr\u00e9existante, avec une mortalit\u00e9 importante. La pouss\u00e9e d\u2019insuffisance cardiaque sur cardiopathie pose \u00e9galement un probl\u00e8me de diagnostic initial et peu retarder le diagnostic du COVID-19 et augmenter la contagiosit\u00e9, \u00e9l\u00e9ment important \u00e0 prendre en consid\u00e9ration en cas de suspicion de l\u2019infection \u00e0 coronavirus chez un patient cardiaque.",
            "cite_spans": [
                {
                    "start": 29,
                    "end": 32,
                    "mention": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "section": "Cardiomyopathie et insuffisance cardiaque ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Un tableau d\u2019insuffisance cardiaque droite avec hypertension pulmonaire a \u00e9t\u00e9 observ\u00e9 surtout dans un contexte de SDRA. Certains patients ont pr\u00e9sent\u00e9 des tableaux de choc cardiog\u00e9nique ou mixte, d\u2019o\u00f9 l\u2019int\u00e9r\u00eat de la r\u00e9alisation d\u2019une TDM thoracique une \u00e9chographie cardiaque et le dosage du peptide natriur\u00e9tique pour clarifier le diagnostic [24], [25]. Dans certaines situations une assistance circulatoire s\u2019impose (ECMO veino-veineuse vs veino-art\u00e9rielle), avec des r\u00e9sultats malheureusement d\u00e9cevants [26].",
            "cite_spans": [
                {
                    "start": 343,
                    "end": 347,
                    "mention": "[24]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 349,
                    "end": 353,
                    "mention": "[25]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 506,
                    "end": 510,
                    "mention": "[26]",
                    "ref_id": "BIBREF25"
                }
            ],
            "section": "Cardiomyopathie et insuffisance cardiaque ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Le COVID-19 est associ\u00e9 \u00e0 un risque thromboembolique \u00e9lev\u00e9, plusieurs facteurs sont incrimin\u00e9s : une immobilisation prolong\u00e9e, L\u2019inflammation responsable d\u2019un \u00e9tat d\u2019hypercoagulabilit\u00e9 et de dysfonction endoth\u00e9liale. Entre autres des taux \u00e9lev\u00e9s de D-dim\u00e8res D (> 1 g/L) \u00e9taient fortement corr\u00e9l\u00e9s \u00e0 une mortalit\u00e9 intra-hospitali\u00e8re \u00e9lev\u00e9e [7]. La thrombo-prophylaxie optimale pour les patients COVID-19, n\u2019est pas encore bien \u00e9tudi\u00e9e, c\u2019est pourquoi il faut appliquer les protocoles d\u00e9j\u00e0 approuv\u00e9s de prophylaxie [27].",
            "cite_spans": [
                {
                    "start": 340,
                    "end": 343,
                    "mention": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 514,
                    "end": 518,
                    "mention": "[27]",
                    "ref_id": "BIBREF26"
                }
            ],
            "section": "Maladie thromboembolique veineuse ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Des auteurs italiens ont d\u00e9crit des cas de MINOCA test\u00e9s positifs pour COVID-19 [28]. Mais jusqu\u2019\u00e0 ce jour aucun cas de SCA dans le cadre de COVID-19 n\u2019a \u00e9t\u00e9 d\u00e9crit. N\u00e9anmoins, les formes graves du COVID-19 peuvent pr\u00e9senter un risque de rupture de la plaque d\u2019ath\u00e9rome chez certain patients [7] d\u2019o\u00f9 le d\u00e9veloppement d\u2019un protocole de soins pour Les patients admis pour SCA dans le cadre d\u2019un COVID-19 [29]. Ci-dessous les Fig. 1, Fig. 2\nr\u00e9sumant la conduite \u00e0 tenir devant les syndromes coronariens aigus avec et sans sus-d\u00e9calage du segment ST, STEMI et NSTEMI. En m\u00eame temps, une diminution des patients hospitalis\u00e9s pour SCA a \u00e9t\u00e9 observ\u00e9e dans la plupart des pays dont la France. Cette baisse peut \u00eatre expliqu\u00e9e par la limitation des activit\u00e9s physiques \u00e0 cause du confinement de la population avec moins de situations de stress susceptibles de d\u00e9clencher la rupture de plaques d\u2019ath\u00e9rome, et par la crainte d\u2019une probable contagion \u00e0 l\u2019h\u00f4pital qui pousse les patients \u00e0 consulter peu m\u00eame en cas de sympt\u00f4mes.",
            "cite_spans": [
                {
                    "start": 80,
                    "end": 84,
                    "mention": "[28]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 292,
                    "end": 295,
                    "mention": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 403,
                    "end": 407,
                    "mention": "[29]",
                    "ref_id": "BIBREF28"
                }
            ],
            "section": "Cas particulier de la prise en charge des syndromes coronariens aigus\u00a0SCA ::: Manifestations cardiovasculaires du COVID-19",
            "ref_spans": [
                {
                    "start": 424,
                    "end": 430,
                    "mention": "Fig. 1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 432,
                    "end": 438,
                    "mention": "Fig. 2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "Le lopinavir/ritonavir peut entra\u00eener un allongement du QT, en particulier chez les patients suivis pour un syndrome de QT long cong\u00e9nital ou ceux qui prennent d\u2019autres m\u00e9dicaments qui allongent l\u2019intervalle QT [30]. Le QTc long si > 440 ms chez l\u2019homme, > 460 ms chez la femme. La dur\u00e9e de l\u2019intervalle QT doit se mesurer \u00e0 des fr\u00e9quences entre 60 et 85/mn dans les d\u00e9rivations o\u00f9 l\u2019onde T est la plus ample et o\u00f9 le retour \u00e0 la ligne iso\u00e9lectrique est le plus net (souvent en V2), depuis le d\u00e9but du QRS jusqu\u2019\u00e0 la jonction entre la tangente de la pente descendante maximale de l\u2019onde T avec la ligne iso\u00e9lectrique Dans ces conditions, QT pathologique si > 440 ms (Fig. 3\n). Si la FC est moins de 60 battements par minute (Bpm) et au-del\u00e0 de 85 bpm, on doit corriger le QT (Bazett), QTc = QTm/V RR.",
            "cite_spans": [
                {
                    "start": 211,
                    "end": 215,
                    "mention": "[30]",
                    "ref_id": "BIBREF29"
                }
            ],
            "section": "Les antiviraux ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": [
                {
                    "start": 667,
                    "end": 673,
                    "mention": "Fig. 3",
                    "ref_id": "FIGREF2"
                }
            ]
        },
        {
            "text": "Un ajustement du QTc s\u2019impose chez les patients ayant des QRS larges, ayant une stimulation ventriculaire ou un bloc de branche gauche complet en appliquant une formule qui prend en consid\u00e9ration la largeur du QRS ; QTC (ajust\u00e9) = QTc \u2212 (QRS \u2212 100).",
            "cite_spans": [],
            "section": "Les antiviraux ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Quand le QTc > 500 ms le risque de mort subite devient significatif, il faut confier le malade \u00e0 une prise en charge sp\u00e9cialis\u00e9e en milieu hospitalier.",
            "cite_spans": [],
            "section": "Les antiviraux ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Le ribavirine et le lopinavir peuvent interagir avec les anticoagulants : la ribavirine a des effets variables sur la warfarine [31] et l\u2019association lopinavir/ritonavir peut n\u00e9cessiter une r\u00e9duction de la dose voire l\u2019arr\u00eat de certains AOD [32], [33].",
            "cite_spans": [
                {
                    "start": 128,
                    "end": 132,
                    "mention": "[31]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 241,
                    "end": 245,
                    "mention": "[32]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 247,
                    "end": 251,
                    "mention": "[33]",
                    "ref_id": "BIBREF32"
                }
            ],
            "section": "Les antiviraux ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Le lopinavir/ritonavir peut interf\u00e9rer avec les inhibiteurs de P2Y12 entra\u00eenant une diminution des concentrations s\u00e9riques du clopidogrel et du prasugrel et une augmentation des concentrations s\u00e9riques du ticagr\u00e9lor [34]. Vu le risque thrombotique/h\u00e9morragique, des approches guid\u00e9es par des tests d\u2019activit\u00e9 plaquettaire peuvent \u00eatre envisageable [35].",
            "cite_spans": [
                {
                    "start": 216,
                    "end": 220,
                    "mention": "[34]",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 348,
                    "end": 352,
                    "mention": "[35]",
                    "ref_id": "BIBREF34"
                }
            ],
            "section": "Les antiviraux ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Les statines peuvent \u00e9galement interagir avec le lopinavir/ritonavir avec un risque majeur de rhabdomyolyse. La lovastatine et la simvastatine, en particulier, sont contre-indiqu\u00e9es en cas de co-administration avec le lopinavir/ritonavir. D\u2019autres statines comme l\u2019atorvastatine et la rosuvastatine, peuvent \u00eatre administr\u00e9 \u00e0 des faibles doses [30]. Le Tableau 3\nr\u00e9sume les interactions des antiviraux et les ajustements th\u00e9rapeutiques possibles [5].",
            "cite_spans": [
                {
                    "start": 344,
                    "end": 348,
                    "mention": "[30]",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 446,
                    "end": 449,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "section": "Les antiviraux ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": [
                {
                    "start": 353,
                    "end": 362,
                    "mention": "Tableau 3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "Il s\u2019agit d\u2019un antipalud\u00e9en de synth\u00e8se qui bloque l\u2019activit\u00e9 virale en augmentant le pH endosomal, avec la d\u00e9monstration in vitro d\u2019une inhibition du virus SRAS-CoV2 [36], [37]. La chloroquine est actuellement au c\u0153ur d\u2019une vaste pol\u00e9mique, Raoult et al. ont expos\u00e9 les r\u00e9sultats de leur \u00e9tude non randomis\u00e9e qui a analys\u00e9 24 patients atteints du coronavirus, les 3/4 \u00e9taient gu\u00e9ris en 6 jours apr\u00e8s avoir re\u00e7u de la chloroquine et surtout en association avec l\u2019azithromycine [38]. Vu qu\u2019il ne s\u2019agissait pas d\u2019une \u00e9tude randomis\u00e9e et vu le nombre limit\u00e9 de patients, cette \u00e9tude a \u00e9t\u00e9 largement critiqu\u00e9e en France. En revanche, il y a eu depuis 2 \u00e9tudes randomis\u00e9es chinoises \u00e0 \u00e9chantillons tr\u00e8s limit\u00e9s, l\u2019une en double aveugle, portant sur (2 \u00d7 15) patients avec des r\u00e9sultats n\u00e9gatifs [39], et l\u2019autre encore ouverte, les r\u00e9sultats pr\u00e9liminaires concernant (2 \u00d7 31) patients se pr\u00e9sentent comme positive en cas d\u2019introduction pr\u00e9coce du traitement [40]. Le minist\u00e8re de la sant\u00e9 au Maroc en concertation avec le comit\u00e9 scientifique et technique du programme national de lutte contre le coronavirus a d\u00e9cid\u00e9 le 23 mars 2020 d\u2019adopter le protocole th\u00e9rapeutique a base d\u2019hydroxychloroquine (200 mg \u00d7 3) et azythromycine (1 g le premier jour puis 500 mg/j pendant 3 jours) dans les diff\u00e9rents h\u00f4pitaux du royaume. Cette d\u00e9cision d\u2019introduction pr\u00e9coce du traitement sous surveillance m\u00e9dicale semble \u00eatre justifi\u00e9e puisque dans les tableaux graves, notamment de SDRA, les pr\u00e9l\u00e8vements \u00e0 la recherche du virus sont souvent n\u00e9gatives [40].",
            "cite_spans": [
                {
                    "start": 167,
                    "end": 171,
                    "mention": "[36]",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 173,
                    "end": 177,
                    "mention": "[37]",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 477,
                    "end": 481,
                    "mention": "[38]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 791,
                    "end": 795,
                    "mention": "[39]",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 954,
                    "end": 958,
                    "mention": "[40]",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 1535,
                    "end": 1539,
                    "mention": "[40]",
                    "ref_id": "BIBREF39"
                }
            ],
            "section": "La chloroquine/hydroxychloroquine ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "La chloroquine a un mode d\u2019action proche de la quinidine et des anti-arythmiques de la classe I de Vaughan-Williams. Ces propri\u00e9t\u00e9s \u00ab quinidine-like \u00bb expliquent l\u2019effet stabilisant de membrane et le risque de la toxicit\u00e9 cardiaque surtout lors des administrations rapides par voie IV ou lors des intoxications aigu\u00ebs volontaires (les doses toxiques chez l\u2019adulte sont de 2 g et les doses l\u00e9tales de 2,5 g). \u00c0 dose th\u00e9rapeutique au long cours, on peut observer parfois un aplatissement de l\u2019onde T et/ou un allongement de l\u2019intervalle QT en particulier lors de la prise concomitante d\u2019un autre m\u00e9dicament allongeant le QT comme l\u2019azithromycine. Ces anomalies n\u2019ont pas de cons\u00e9quence clinique et r\u00e9gressent apr\u00e8s quelques jours [41]. Les troubles du rythmes et/ou conductifs graves sont surtout observ\u00e9s \u00e0 des doses toxiques (\u2265 2 g) n\u00e9cessitant une prise en charge sp\u00e9ciale [42].",
            "cite_spans": [
                {
                    "start": 728,
                    "end": 732,
                    "mention": "[41]",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 874,
                    "end": 878,
                    "mention": "[42]",
                    "ref_id": "BIBREF41"
                }
            ],
            "section": "La chloroquine/hydroxychloroquine ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "De rares observations de cardiomyopathie restrictive/dilat\u00e9e ont \u00e9t\u00e9 rapport\u00e9 lors des traitements au long cours [43].",
            "cite_spans": [
                {
                    "start": 113,
                    "end": 117,
                    "mention": "[43]",
                    "ref_id": "BIBREF42"
                }
            ],
            "section": "La chloroquine/hydroxychloroquine ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "En raison de l\u2019inhibition du CYP2D6, la chloroquine peut augmenter la concentration de certains b\u00eata-bloquants d\u2019o\u00f9 la n\u00e9cessit\u00e9 d\u2019une surveillance de la FC et de la pression art\u00e9rielle et ajustement sp\u00e9cialis\u00e9es des doses.",
            "cite_spans": [],
            "section": "La chloroquine/hydroxychloroquine ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Une surveillance plus proche est pr\u00e9conis\u00e9e en particulier en cas de co-prescription avec l\u2019azithromycine, un ECG doit \u00eatre r\u00e9alis\u00e9 avant le d\u00e9but du traitement avec la mesure du QTc puis 3 \u00e0 4 h suivant la premi\u00e8re administration (au concentration max suppos\u00e9 de l\u2019hydroxychloroquine \u00b1 azithromycine), puis 2 fois par semaine pendant la dur\u00e9e du traitement et en cas de sympt\u00f4me pouvant faire \u00e9voquer un trouble du rythme cardiaque (palpitations brusques et br\u00e8ves, syncope, crise comitiale\u2026). Si le QTc est \u2265 500 ms, le traitement doit \u00eatre diminu\u00e9 ou arr\u00eat\u00e9 en fonction de la d\u00e9cision du clinicien, et un monitoring cardiaque continu mis en place jusqu\u2019\u00e0 normalisation de l\u2019ECG [44].",
            "cite_spans": [
                {
                    "start": 681,
                    "end": 685,
                    "mention": "[44]",
                    "ref_id": "BIBREF43"
                }
            ],
            "section": "La chloroquine/hydroxychloroquine ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "Le risque de trouble du rythme est major\u00e9 en cas d\u2019hypokali\u00e9mie fr\u00e9quente dans les sepsis. Tout signe \u00e9voquant une instabilit\u00e9 rythmique doit inciter \u00e0 faire un ECG.",
            "cite_spans": [],
            "section": "La chloroquine/hydroxychloroquine ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "En effet le risque de torsades de pointes est r\u00e9el au-del\u00e0 d\u2019une mesure du QTc, sup\u00e9rieure \u00e0 500 ms, une surveillance de la kali\u00e9mie et de la magn\u00e9s\u00e9mie dans ces rares cas s\u2019impose, et l\u2019\u00e9quipe soignante doit \u00eatre pr\u00eate \u00e0 monter une sonde provisoire de stimulation si n\u00e9cessaire. Il faut toujours corriger ces facteurs extrins\u00e8ques pour permettre une prescription dans les meilleures conditions.",
            "cite_spans": [],
            "section": "La chloroquine/hydroxychloroquine ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "La Fig. 4\npropose un sch\u00e9ma de surveillance cardiologique pour les patients sous traitement \u00e0 base d\u2019hydroxychloroquine. (Sch\u00e9ma de surveillance all\u00e9g\u00e9 adapt\u00e9 au contexte de l\u2019\u00e9pid\u00e9mie).",
            "cite_spans": [],
            "section": "La chloroquine/hydroxychloroquine ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": [
                {
                    "start": 3,
                    "end": 9,
                    "mention": "Fig. 4",
                    "ref_id": "FIGREF3"
                }
            ]
        },
        {
            "text": "Propos\u00e9e pour les formes graves du COVID-19 dont on conna\u00eet ses effets sur le m\u00e9tabolisme hydrosod\u00e9 avec le risque d\u2019HTA, peut \u00e9galement interagir avec la warfarine via un m\u00e9canisme non d\u00e9crit.",
            "cite_spans": [],
            "section": "La m\u00e9thylprednisolone ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "L\u2019observance th\u00e9rapeutique peut \u00eatre difficile chez les patients cardiaques admis pour une infection \u00e0 COVID-19 grave avec un risque de d\u00e9compensation et de d\u00e9c\u00e8s. Il faut souligner la diminution de la r\u00e9action immunitaire chez les patients prenant des cortico\u00efdes sans une indication obligatoire, risquant d\u2019aggraver le tableau clinique.",
            "cite_spans": [],
            "section": "La m\u00e9thylprednisolone ::: Interactions c\u0153ur/traitement du COVID-19",
            "ref_spans": []
        },
        {
            "text": "L\u2019enzyme de conversion de l\u2019angiotensine 2, prot\u00e9ine membranaire int\u00e9grale de type I qui sert de nombreux fonctions physiologiques, semble jouer un r\u00f4le pour la p\u00e9n\u00e9tration du virus au niveau cellulaire comme cela a \u00e9t\u00e9 d\u00e9montr\u00e9 dans plusieurs \u00e9tudes sur le SRAS-CoV2 [10].",
            "cite_spans": [
                {
                    "start": 268,
                    "end": 272,
                    "mention": "[10]",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "Le d\u00e9bat pour l\u2019arr\u00eat des m\u00e9dicaments bloqueurs du syst\u00e8me r\u00e9nine-angiotensine et aldost\u00e9rone",
            "ref_spans": []
        },
        {
            "text": "Il est fortement exprim\u00e9 dans les cellules alv\u00e9olaires pulmonaires, fournissant le principal site d\u2019entr\u00e9e virus chez des h\u00f4tes humains [21], [18].",
            "cite_spans": [
                {
                    "start": 136,
                    "end": 140,
                    "mention": "[21]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 142,
                    "end": 146,
                    "mention": "[18]",
                    "ref_id": "BIBREF17"
                }
            ],
            "section": "Le d\u00e9bat pour l\u2019arr\u00eat des m\u00e9dicaments bloqueurs du syst\u00e8me r\u00e9nine-angiotensine et aldost\u00e9rone",
            "ref_spans": []
        },
        {
            "text": "Le coronavirus se lie aux cellules exprimant les r\u00e9cepteurs viraux appropri\u00e9s, en particulier les r\u00e9cepteurs ACE2 [45] sugg\u00e8rent que les inhibiteurs de l\u2019ECA (IEC) et les bloqueurs des r\u00e9cepteurs de l\u2019angiotensine (ARAII) peut r\u00e9guler positivement l\u2019ACE2, augmentant ainsi la sensibilit\u00e9 au virus. En revanche, d\u2019autres \u00e9tudes montrent que l\u2019IEC/ARAII peut potentialiser la fonction de protection pulmonaire de l\u2019ACE2, qui est un inhibiteur de l\u2019angiotensine II. Ainsi, les implications th\u00e9rapeutiques pour la th\u00e9rapie IEC/ARAII pendant L\u2019infection \u00e0 COVID-19 ne sont pas claires. Dans l\u2019ensemble, les donn\u00e9es sont insuffisantes pour sugg\u00e9rer des connexions m\u00e9caniques entre la th\u00e9rapie IEC/ARAII et la contamination par le COVID-19.",
            "cite_spans": [
                {
                    "start": 114,
                    "end": 118,
                    "mention": "[45]",
                    "ref_id": "BIBREF44"
                }
            ],
            "section": "Le d\u00e9bat pour l\u2019arr\u00eat des m\u00e9dicaments bloqueurs du syst\u00e8me r\u00e9nine-angiotensine et aldost\u00e9rone",
            "ref_spans": []
        },
        {
            "text": "Ainsi en absence de donn\u00e9es cliniques, selon la derni\u00e8re publication dans le NEJM, the American College of Cardiology, and the American Society of Heart Failure [46], on ne recommande pas l\u2019arr\u00eat du traitement IEC, ARAII chez les patients atteints du nouveau coronavirus d\u00e9j\u00e0 sous traitement IEC/ARAII pour HTA, insuffisance cardiaque, ou cardiopathie isch\u00e9mique sauf dans certaines situations qui contre-indiquent leurs continuations (insuffisance r\u00e9nale, sepsis, \u00e9tat de choc) (Fig. 5\n).",
            "cite_spans": [
                {
                    "start": 161,
                    "end": 165,
                    "mention": "[46]",
                    "ref_id": "BIBREF45"
                }
            ],
            "section": "Le d\u00e9bat pour l\u2019arr\u00eat des m\u00e9dicaments bloqueurs du syst\u00e8me r\u00e9nine-angiotensine et aldost\u00e9rone",
            "ref_spans": [
                {
                    "start": 480,
                    "end": 486,
                    "mention": "Fig. 5",
                    "ref_id": "FIGREF4"
                }
            ]
        },
        {
            "text": "Les \u00e9pid\u00e9mies de maladies respiratoires virales menacent la sant\u00e9 publique et peuvent avoir des manifestations extra-pulmonaires notamment cardiologiques avec des cons\u00e9quences \u00e0 la phase aigu\u00eb et \u00e0 long terme. Les maladies cardiovasculaires pr\u00e9existantes peuvent contribuer \u00e0 des r\u00e9sultats cliniques pr\u00e9coces d\u00e9favorables. La prise en charge interdisciplinaire des cas s\u00e9v\u00e8res et un suivi clinique prolong\u00e9 sont donc essentiels.",
            "cite_spans": [],
            "section": "Conclusion",
            "ref_spans": []
        },
        {
            "text": "Les auteurs d\u00e9clarent ne pas avoir de liens d\u2019int\u00e9r\u00eats.",
            "cite_spans": [],
            "section": "D\u00e9claration de liens d\u2019int\u00e9r\u00eats",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Tableau 1: Fr\u00e9quence relative des facteurs de risque cardiovasculaire ou des conditions cardiovasculaires sous-jacentes dans la cohorte COVID-19.\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Tableau 2: Principales manifestations cardiaques et extra-cardiaques fr\u00e9quentes dans le COVID-19.\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Tableau 3: Interactions des antiviraux et ajustement th\u00e9rapeutiques.\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Fig. 1: Prise en charge du syndrome coronarien aigu sans sus-d\u00e9calage du segment ST NSTEMI dans le COVID-19.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Fig. 2: Prise en charge du syndrome coronarien aigu avec sus-d\u00e9calage du segment ST STEMI dans le COVID 19.",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Fig. 3: Mesure QTc.",
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Fig. 4: Surveillance cardiologique du traitement \u00e0 l\u2019hydroxychloroquine COVID 19.",
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Fig. 5: Relation entre la pathog\u00e9nicit\u00e9 virale, les r\u00e9cepteurs ACE2 et la protection pulmonaire, ainsi que les effets potentiels sur l\u2019inhibition de la r\u00e9nine-angiotensine-aldost\u00e9rone.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Grippe",
            "authors": [
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Lina",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "EMC - AKOS (Trait\u00e9 de M\u00e9decine)",
            "volume": "12",
            "issn": "1",
            "pages": "1-11",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "The recent wave of \u2018Spanish\u2019 flu historiography",
            "authors": [
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Howard",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Soc Hist Med",
            "volume": "27",
            "issn": "4",
            "pages": "789-808",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Les infections \u00e0 coronavirus humains",
            "authors": [
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Kin",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Vabret",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Rev Francoph Lab",
            "volume": "2016",
            "issn": "487",
            "pages": "25-33",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Characteristics of COVID-19\u00a0patients dying in Italy",
            "authors": [],
            "year": 2020,
            "venue": "Report based on available data",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Cardiovascular considerations for patients, health care workers, and health systems during the Coronavirus disease 2019 (COVID-19) pandemic",
            "authors": [
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Driggin",
                    "suffix": ""
                },
                {
                    "first": "M.V.",
                    "middle": [],
                    "last": "Madhavan",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Bikdeli",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Chuich",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Laracy",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Bondi-Zoccai",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Am Coll Cardiol",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Clinical characteristics of Coronavirus Disease 2019\u00a0in China",
            "authors": [
                {
                    "first": "W.J.",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z.Y.",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19\u00a0in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Clinical characteristics of 138\u00a0hospitalized patients with 2019\u00a0novel Coronavirus-infected pneumonia in Wuhan",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "China. JAMA",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Clinical features of patients infected with 2019\u00a0novel coronavirus in Wuhan, China",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497-506",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Clinical predictors of mortality due to COVID-19\u00a0based on an analysis of data of 150\u00a0patients from Wuhan, China",
            "authors": [
                {
                    "first": "Q.",
                    "middle": [],
                    "last": "Ruan",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "W.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Intensive Care Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019\u00a0pneumonia in Wuhan, China",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA Intern Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "SARS-coronavirus modulation of myocardial ACE2\u00a0expression and inflammation in patients with SARS",
            "authors": [
                {
                    "first": "G.Y.",
                    "middle": [],
                    "last": "Oudit",
                    "suffix": ""
                },
                {
                    "first": "Z.",
                    "middle": [],
                    "last": "Kassiri",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "P.P.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "S.M.",
                    "middle": [],
                    "last": "Poutanen",
                    "suffix": ""
                },
                {
                    "first": "J.M.",
                    "middle": [],
                    "last": "Penninger",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Eur J Clin Invest",
            "volume": "39",
            "issn": "",
            "pages": "618-625",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "",
            "authors": [
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Niu",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Clinical characteristics and outcomes of patients with myocardial infarction, myocardial injury, and nonelevated troponins",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Sarkisian",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Saaby",
                    "suffix": ""
                },
                {
                    "first": "T.S.",
                    "middle": [],
                    "last": "Poulsen",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Am J Med",
            "volume": "129",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Fourth universal definition of myocardial infarction",
            "authors": [
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Thygesen",
                    "suffix": ""
                },
                {
                    "first": "J.S.",
                    "middle": [],
                    "last": "Alpert",
                    "suffix": ""
                },
                {
                    "first": "A.S.",
                    "middle": [],
                    "last": "Jaffe",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Am Coll Cardiol",
            "volume": "72",
            "issn": "",
            "pages": "2231-2264",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Clinical course and outcomes of critically ill patients with SARS-CoV-2\u00a0pneumonia in Wuhan, China: a single-centered, retrospective, observational study",
            "authors": [
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Respir Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis",
            "authors": [
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Lippi",
                    "suffix": ""
                },
                {
                    "first": "C.J.",
                    "middle": [],
                    "last": "Lavie",
                    "suffix": ""
                },
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Sanchis-Gomar",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Prog Cardiovasc Dis",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin",
            "authors": [
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X.L.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "X.G.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Pathological findings of COVID-19\u00a0associated with acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "Z.",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Respir Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury",
            "authors": [
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Sci China Life Sci",
            "volume": "63",
            "issn": "",
            "pages": "364-374",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province",
            "authors": [
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Y.Y.",
                    "middle": [],
                    "last": "Fang",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Chin Med J (Engl)",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "SARS-CoV-2: a potential novel etiology of fulminant myocarditis",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "D.W.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Herz",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Acute respiratory distress syndrome: the Berlin Definition",
            "authors": [
                {
                    "first": "A.D.T.",
                    "middle": [],
                    "last": "Force",
                    "suffix": ""
                },
                {
                    "first": "V.M.",
                    "middle": [],
                    "last": "Ranieri",
                    "suffix": ""
                },
                {
                    "first": "G.D.",
                    "middle": [],
                    "last": "Rubenfeld",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "JAMA",
            "volume": "307",
            "issn": "",
            "pages": "2526-2533",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Karmpaliotis",
                    "suffix": ""
                },
                {
                    "first": "A.J.",
                    "middle": [],
                    "last": "Kirtane",
                    "suffix": ""
                },
                {
                    "first": "C.P.",
                    "middle": [],
                    "last": "Ruisi",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Chest",
            "volume": "131",
            "issn": "",
            "pages": "964-971",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation",
            "authors": [
                {
                    "first": "G.",
                    "middle": [],
                    "last": "MacLaren",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Fisher",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Brodie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "American Society of Hematology 2018\u00a0guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy",
            "authors": [
                {
                    "first": "D.M.",
                    "middle": [],
                    "last": "Witt",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Nieuwlaat",
                    "suffix": ""
                },
                {
                    "first": "N.P.",
                    "middle": [],
                    "last": "Clark",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Blood Adv",
            "volume": "2",
            "issn": "",
            "pages": "3257-3291",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Pan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Intensive Care Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "",
            "authors": [],
            "year": 2013,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin",
            "authors": [
                {
                    "first": "D.D.",
                    "middle": [],
                    "last": "DeCarolis",
                    "suffix": ""
                },
                {
                    "first": "A.D.",
                    "middle": [],
                    "last": "Westanmo",
                    "suffix": ""
                },
                {
                    "first": "Y.C.",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "A.L.",
                    "middle": [],
                    "last": "Boese",
                    "suffix": ""
                },
                {
                    "first": "M.A.",
                    "middle": [],
                    "last": "Walquist",
                    "suffix": ""
                },
                {
                    "first": "T.S.",
                    "middle": [],
                    "last": "Rector",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Ann Pharmacother",
            "volume": "50",
            "issn": "",
            "pages": "909-917",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor",
            "authors": [
                {
                    "first": "C.E.",
                    "middle": [],
                    "last": "Frost",
                    "suffix": ""
                },
                {
                    "first": "W.",
                    "middle": [],
                    "last": "Byon",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Br J Clin Pharmacol",
            "volume": "79",
            "issn": "",
            "pages": "838-846",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects",
            "authors": [
                {
                    "first": "W.",
                    "middle": [],
                    "last": "Mueck",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Kubitza",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Becka",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Br J Clin Pharmacol",
            "volume": "76",
            "issn": "",
            "pages": "455-466",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF33": {
            "title": "Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites",
            "authors": [
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Marsousi",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Daali",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Fontana",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Clin Pharmacokinet",
            "volume": "57",
            "issn": "",
            "pages": "1347-1354",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF34": {
            "title": "International expert consensus on switching platelet P2Y12\u00a0receptor-inhibiting therapies",
            "authors": [
                {
                    "first": "D.J.",
                    "middle": [],
                    "last": "Angiolillo",
                    "suffix": ""
                },
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Rollini",
                    "suffix": ""
                },
                {
                    "first": "R.F.",
                    "middle": [],
                    "last": "Storey",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Circulation",
            "volume": "136",
            "issn": "",
            "pages": "1955-1975",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF35": {
            "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Res",
            "volume": "30",
            "issn": "",
            "pages": "269-271",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF36": {
            "title": "Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19\u00a0associated pneumonia in clinical studies",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Z.",
                    "middle": [],
                    "last": "Tian",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Biosci Trends",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF37": {
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "20",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF38": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.3785/j.issn.1008-9292.2020.03.03"
                ]
            }
        },
        "BIBREF39": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.22.20040758"
                ]
            }
        },
        "BIBREF40": {
            "title": "Cardiotoxicity of antimalarial drugs",
            "authors": [
                {
                    "first": "N.J.",
                    "middle": [],
                    "last": "White",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Lancet Infect Dis",
            "volume": "7",
            "issn": "",
            "pages": "549-558",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF41": {
            "title": "Treatment of acute chloroquine poisoning: a 5-year experience",
            "authors": [
                {
                    "first": "J.L.",
                    "middle": [],
                    "last": "Clemessy",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Taboulet",
                    "suffix": ""
                },
                {
                    "first": "J.R.",
                    "middle": [],
                    "last": "Hoffman",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Crit Care Med",
            "volume": "24",
            "issn": "7",
            "pages": "1189-1195",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF42": {
            "title": "La toxicit\u00e9 cardiaque des antipalud\u00e9ens",
            "authors": [
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Le\u00a0Maitre",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Med Mal Infect",
            "volume": "29",
            "issn": "Supp. I",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF43": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF44": {
            "title": "Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2\u00a0receptor",
            "authors": [
                {
                    "first": "X.Y.",
                    "middle": [],
                    "last": "Ge",
                    "suffix": ""
                },
                {
                    "first": "J.L.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X.L.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Nature",
            "volume": "503",
            "issn": "",
            "pages": "535-538",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF45": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}